These data were achieved by stimulating CLL cells with pharmacological concentrations (10–100 ng/mL) of IL-21 in vitro and differ from recent findings obtained under more physiological conditions. This evidence concerns the gene IL21 and B-cell chronic lymphocytic leukemia.